Free Trial

Relmada Therapeutics (RLMD) Earnings Date, Estimates & Call Transcripts

Relmada Therapeutics logo
$7.35 -0.06 (-0.81%)
Closing price 04:00 PM Eastern
Extended Trading
$7.38 +0.04 (+0.48%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Relmada Therapeutics Earnings Summary

Relmada Therapeutics issued Q4 2025 earnings on March 19, 2026, reporting an EPS of -$0.27, which missed analysts' consensus estimates of -$0.14 by $0.13. With a trailing EPS of -$1.45, Relmada Therapeutics' earnings are expected to decrease next year, from ($0.72) to ($1.18) per share.

Upcoming
Earnings Date
May. 11After Market ClosesEstimated
Consensus EPS
(Mar. 19)
-$0.14
Actual EPS
(Mar. 19)
-$0.27 Missed By -$0.13

Q4 2025 Earnings Resources

RLMD Upcoming Earnings

Relmada Therapeutics' Q1 2026 earnings is estimated for Monday, May 11, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Get Relmada Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Relmada Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

RLMD Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Relmada Therapeutics Analyst EPS Estimates

Current Year EPS Consensus Estimate
($0.72) EPS
Next Year EPS Consensus Estimate
($1.18) EPS

Relmada Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/11/2026
(Estimated)
-------
3/19/2026Q4 2025-$0.14-$0.27 -$0.13-$0.27--
11/13/2025Q3 2025-$0.04-$0.30 -$0.26-$0.30--
8/7/2025Q2 2025-$0.25-$0.30 -$0.05-$0.30--
5/12/2025Q1 2025-$0.31-$0.58 -$0.27-$0.58--
3/27/2025Q4 2024-$0.70-$0.62+$0.08-$0.62--
11/7/2024Q3 2024-$0.65-$0.72 -$0.07-$0.72--
8/7/2024Q2 2024-$0.83-$0.59+$0.24-$0.59--
5/8/2024Q1 2024-$0.90-$0.72+$0.18-$0.72--

Data powered by Fiscal.ai.

Relmada Therapeutics Earnings - Frequently Asked Questions

Relmada Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 11th, 2026 based off last year's report dates. Learn more on RLMD's earnings history.

In the previous quarter, Relmada Therapeutics (NASDAQ:RLMD) missed the analysts' consensus estimate of ($0.14) by $0.13 with a reported earnings per share (EPS) of ($0.27). Learn more on analysts' earnings estimate vs. RLMD's actual earnings.

The conference call for Relmada Therapeutics' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Relmada Therapeutics' latest earnings report can be read online.
Read Transcript

Relmada Therapeutics (NASDAQ:RLMD) has a recorded net income of -$57.38 million. RLMD has generated -$1.45 earnings per share over the last four quarters.

Relmada Therapeutics' earnings are expected to decrease from ($0.72) per share to ($1.18) per share in the next year.


This page (NASDAQ:RLMD) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners